Phase 2 N=3 Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=27 An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
Malignant Melanoma
Primary: Maximum Tolerated Dose (MTD) of IMC-20D7S — 20 mg/kg q2w
Phase 3 N=1,383 Evaluation of Pigmented Skin Lesions With MelaFind(R) System
Melanoma
Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05
N/A N=1,000 Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access
Melanoma
Primary: Number of Participants Who Completed SSE at Specified Time Points — 217; 242; 475; 238 Participants — p=<0.001
N/A N=54 Skin Care Behaviors Among Melanoma Survivors and Their Families
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
N/A N=368 Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
N/A N=54 Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Cutaneous Melanoma
Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05
Phase 3 N=436 Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
Cutaneous Malignant Melanoma
Primary: Relapse Free Survival — 41; 32 Participants — p== 0.324
N/A N=75,771 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer
Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
N/A N=420 Skin Self-Examination Education During Mammography
Melanoma
Primary: Number of Participants That Performed a Skin Self-Examination at 3-months — 161; 185 Participants — p=0.12
Phase 2 N=52 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Mucosal Lentiginous Melanoma · Acral Lentiginous Malignant Melanoma
Primary: 2-month Progression-free Survival Rate — .52; .52 proportion of patients
Phase 2 N=24 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Phase 2 N=15 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Phase 2 N=90 Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma
Cancer
Primary: Percentage of Agreement Between the Detection of SLNs — 69.7 percentage complete agreement
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
Phase 2 N=187 Phase IIB TL + YCWP + DC in Melanoma
Melanoma
Primary: Disease Free Survival Assessment — 32; 30; 31; 30 Participants
Phase 2 N=1,009 A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Phase 2 N=104 Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants
N/A N=441 Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma
Stage 0 Skin Melanoma · Stage I Skin Melanoma · Stage IA Skin Melanoma
Primary: Sun Protection Behavior Index — 3.54; 3.37 scores on a scale
Phase 2 N=20 Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=158 Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Melanoma · Malignant Melanoma · Melanoma, Experimental
Primary: Clinical Response — 1; 3; 3; 2 Participants
N/A N=43 Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
Nevi
Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations
Phase 2 N=102 Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Metastatic Melanoma · Skin Cancer
Primary: Percentage of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression) — 27.5; 27.1; 19.6; 37.5 Percentage of participants
N/A N=50 Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma
Recurrent Melanoma
Primary: Sentinel Lymph Nodes (SLN) Mapping — 25; 25; 25; 4 Sentinel lymph nodes
Phase 2 N=20 Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
N/A N=600 Skin Health Online for Melanoma: Better Risk Assessment
Melanoma (Skin)
Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants